Combating Endocrine Resistance in Breast Cancer With Novel Agents, Combinations

Video

This video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.

In this video, Steffi Oesterreich, PhD, of the University of Pittsburgh Cancer Institute in Pennsylvania, reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in hormone receptor (HR)-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.

Oesterreich chaired a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content
Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

Evaluating the Rapidly Changing ADC Landscape in HR+/HER2– Breast Cancer

ONCOLOGY Staff
May 21st 2025
Article

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

Erika King;Elisa Port;Borna Mohabbatizadeh;Christina Weltz;Jacquelyn Dillon;Jacquelyn Amenta;Mayuri Jain
May 19th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Leslie Elmore;Neil Carleton;Michael S. Cowher;Rohit Bhargava;Emilia Diego;Kristin Lupinacci;Meaghan Marley;Qurat Ul Ain Sabih;Atilla Soran, MD, MPH;Jennifer Steiman;Ronald Johnson;Erin Bayley;Priscilla F. Mcauliffe, MD, PhD
May 17th 2025
Article
ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer

Ariana Pelosci
May 16th 2025
Article

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.